3687 Results for "

2A3

" in MedChemExpress (MCE) Product Catalog:
Products (3687)

3687 Results for "2A3" in MCE Product Catalog:

43
43 Cited Publications
Cat. No.: HY-119240
CAS No.: 324759-76-4
Purity:  99.05%
Target:  

PERK Autophagy

Research Areas:  

Neurological Disease Cancer

CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-18708
CAS No.: 1346242-81-6
Synonyms: JNJ-42756493
Target:  

FGFR Apoptosis

Research Areas:  

Cancer

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-13330
CAS No.: 1035270-39-3
Purity:  99.85%
Synonyms: AZD4547; ADSK091
Target:  

FGFR

Research Areas:  

Cancer

Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC50s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-10442
CAS No.: 102052-95-9
Purity:  99.80%
Synonyms: DZNep; 3-Deazaneplanocin
3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor [2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-12186
CAS No.: 120964-45-6
Purity:  99.89%
Synonyms: DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride
3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor [2]. 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor . 3-Deazaneplanocin A hydrochloride also has anti-orthopoxvirus and anti-variola activities .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-16954
CAS No.: 1818885-28-7
ARV-825 is a BET protein PROTAC degrader that recruits cereblon, and it targets BRD2, BRD3, and BRD4 for degradation via the ubiquitin-proteasome pathway. ARV-825 downregulates c-MYC, PLK1, MYCN, CDK4/6, JAK2, pSTAT3/5, PIM1, and Bcl-xL, upregulates p21 and p27, and modulates H3K27Ac-mediated transcription, the G2/M checkpoint, the Wnt/β-catenin pathway, and amino acid transport pathways. ARV-825 induces G1 phase cell cycle arrest, caspase 3/PARP-mediated apoptosis, DNA damage, and reactive oxygen species (ROS) production, reduces mitochondrial respiration, and simultaneously inhibits cell proliferation, clonogenic growth, and cell migration. ARV-825 is used in research on gastric cancer, leukemia, neuroblastoma, and cholangiocarcinoma .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-15176C
CAS No.: 2517456-88-9
Synonyms: RR82 trihydrochloride
Pyridostatin (RR82) trihydrochloride is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin trihydrochloride also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin trihydrochloride interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin trihydrochloride exhibits antiproliferative and antiviral activities. Pyridostatin trihydrochloride can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-15176B
CAS No.: 1472611-44-1
Purity:  99.54%
Synonyms: RR82 TFA
Pyridostatin (RR82) TFA is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin TFA also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin TFA interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin TFA exhibits antiproliferative and antiviral activities. Pyridostatin TFA can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-100972
CAS No.: 1949837-12-0
Purity:  98.87%
ARV-771 is a BET PROTAC degrader, with Kd values of 34, 4.7, 8.3, 7.6, 9.6 and 7.6 nM against BRD2 (1), BRD2 (2), BRD3 (1), BRD3 (2), BRD4 (1) and BRD4 (2) , respectively. ARV-771 inhibits the transcription of AR/AR-v7 and its downstream target genes. By degrading BRD4 protein, ARV-771 enhances the sensitivity of prostate cancer cells to ferroptosis, suppresses cancer cell viability, and induces apoptosis. ARV-771 downregulates the levels of BRD4, c-MYC and AR-V7 in tumor tissues and inhibits tumor tissue growth. ARV-771 can be used in prostate cancer-related research .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-18300
CAS No.: 1206161-97-8
Synonyms: GLPG0634
Target:  

JAK HIV

Research Areas:  

Cancer

Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-18300A
CAS No.: 1802998-75-9
Synonyms: GLPG0634 maleate
Target:  

JAK HIV

Research Areas:  

Inflammation/Immunology

Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values ​​of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-B0498
CAS No.: 130641-38-2
Synonyms: AF2838
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-12009
CAS No.: 635702-64-6
Purity:  99.99%
Synonyms: GW786034 Hydrochloride
Research Areas:  

Cancer

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-10208
CAS No.: 444731-52-6
Purity:  99.91%
Synonyms: GW786034
Research Areas:  

Cancer

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-12164
CAS No.: 726169-73-9
Purity:  99.13%
Synonyms: MGCD0103
Target:  

HDAC Autophagy Apoptosis

Research Areas:  

Cancer

Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-107425
CAS No.: 1797406-69-9
Purity:  99.86%
Research Areas:  

Cancer

MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-109099
CAS No.: 1513857-77-6
Purity:  99.84%
Synonyms: INCB054828
Target:  

FGFR

Research Areas:  

Cancer

Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-13032B
CAS No.: 1895049-20-3
Purity:  97.04%
Synonyms: GSK 525762C; I-BET 762 besylate
Research Areas:  

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-10510
CAS No.: 501437-28-1
Purity:  99.43%
Research Areas:  

Cancer

BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC50s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-N0484
CAS No.: 2586-96-1
Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
loading...
    loading...